Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1219354 | 0.86 | — | — | |
| SCHEMBL16892353 | 0.85 | CHRM2 (0.42) | ALDH1A1HPGDLCKTSHRCHRM2 | |
| SCHEMBL9797780 | 0.83 | TSHR (0.43) | ALDH1A1HPGDLCKTSHRCHRM2 | |
| SCHEMBL6608458 | 0.83 | ALDH1A1 (0.44) | ALDH1A1HPGDLCKTSHRTDP1 | |
| SCHEMBL7782415 | 0.80 | ALDH1A1 (0.42) | ALDH1A1HPGDLCKTSHRTDP1 | |
| SCHEMBL11501695 | 0.80 | CHRM2 (0.43) | ALDH1A1TSHRCHRM2 | |
| SCHEMBL13609722 | 0.79 | TSHR (0.52) | ALDH1A1HPGDLCKTSHR | |
| SCHEMBL16639235 | 0.79 | LCK (0.40) | ALDH1A1HPGDLCKTSHRCHRM2 | |
| SCHEMBL1219362 | 0.78 | — | — | |
| SCHEMBL18281275 | 0.78 | TSHR (0.48) | ALDH1A1HPGDLCKTSHRCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700638-B2 | 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex | N. V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| US-20070021482-A1 | 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex | N.V. ORGANON (NL) | 2007-01-25 | — | — | US | disclosed |
| EP-1678144-A1 | 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX | Akzo Nobel N.V. (NL) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040131-A1 | 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | AKZO NOBEL N.V. (NL) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021482-A1 | 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex | GABRB1, GABRA5, GABRB2 | ALDH1A1 541/4885HPGD 2676/4885LCK 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.